Combination of the ceftazidime and the cellulase had significant anti-biofilm effects, including inhibiting biofilm formation and eradicating biofilm in P. aeruginosa. These data suggest that glycoside hydrolase therapy as a novel strategy has the potential to enhance antibiotic efficacy and help resolve biofilm-associated wound infections caused by this pathogen.
Oral Administration
Ceftazidime does not have a direct oral formulation; it is typically administered intravenously or intramuscularly, with oral alternatives like cefixime or cefpodoxime considered when Pseudomonas coverage is not required.
Ceftazidime is a third-generation cephalosporin with strong anti-Pseudomonas activity, but it cannot be taken orally because its chemical structure is unstable in stomach acid and it has poor gastrointestinal absorption, making oral administration ineffective for achieving therapeutic blood levels.
It is primarily given via intravenous (IV) or intramuscular (IM) injection for serious infections such as meningitis, sepsis, or Pseudomonas infections.